金域医学
(603882)
| 流通市值：128.98亿 | | | 总市值：130.45亿 |
| 流通股本：4.58亿 | | | 总股本：4.63亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 2,884,285,424.41 | 1,350,977,738.08 | 6,030,452,713.41 | 4,538,151,376.33 |
| 营业总成本 | 2,656,077,919.64 | 1,292,025,224.52 | 5,814,342,183.77 | 4,282,602,888.45 |
| 其他经营收益 | | | | |
| 营业利润 | 268,640,223.67 | 66,269,455.61 | -129,870,790.27 | -63,006,298.9 |
| 利润总额 | 257,323,219.03 | 61,072,831.86 | -181,611,034.17 | -82,117,770.48 |
| 净利润 | 211,621,878.34 | 47,882,754.88 | -178,600,830.71 | -88,794,076.93 |
| 每股收益 | | | | |
| 其他综合收益 | -24,165,066.37 | -15,756,437.56 | -13,554,392.73 | -8,139,141.33 |
| 综合收益总额 | 187,456,811.97 | 32,126,317.32 | -192,155,223.44 | -96,933,218.26 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 6,146,526,602.53 | 6,187,258,989.57 | 6,613,006,609.82 | 6,727,870,048.76 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,992,037,097.07 | 3,013,148,731.24 | 2,991,523,715.48 | 2,986,035,762.08 |
| 资产总计 | 9,138,563,699.6 | 9,200,407,720.81 | 9,604,530,325.3 | 9,713,905,810.84 |
| 流动负债: | | | | |
| 流动负债合计 | 1,962,255,400.47 | 1,977,975,797.23 | 2,042,154,195.91 | 2,141,899,809.27 |
| 非流动负债: | | | | |
| 非流动负债合计 | 726,611,481.92 | 739,422,800.64 | 703,826,041.81 | 618,233,908.77 |
| 负债合计 | 2,688,866,882.39 | 2,717,398,597.87 | 2,745,980,237.72 | 2,760,133,718.04 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 6,314,304,429.52 | 6,348,753,585.95 | 6,729,386,755.73 | 6,828,436,021.6 |
| 股东权益合计 | 6,449,696,817.21 | 6,483,009,122.94 | 6,858,550,087.58 | 6,953,772,092.8 |
| 负债和股东权益合计 | 9,138,563,699.6 | 9,200,407,720.81 | 9,604,530,325.3 | 9,713,905,810.84 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,945,520,533.55 | 1,354,749,024.94 | 6,976,591,310.02 | 4,973,686,069.04 |
| 经营活动现金流出小计 | 2,702,900,064.75 | 1,311,319,338.89 | 5,774,582,042.92 | 4,301,778,174.56 |
| 经营活动产生的现金流量净额 | 242,620,468.8 | 43,429,686.05 | 1,202,009,267.1 | 671,907,894.48 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 23,011,483.49 | 6,771,560.44 | 99,433,636.21 | 69,898,072.03 |
| 投资活动现金流出小计 | 243,667,789.41 | 143,101,126.21 | 470,405,734.18 | 332,678,444.24 |
| 投资活动产生的现金流量净额 | -220,656,305.92 | -136,329,565.77 | -370,972,097.97 | -262,780,372.21 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 152,808,533.58 | 15,908,533.58 | 221,894,530.96 | 113,745,121.55 |
| 筹资活动现金流出小计 | 773,734,826.94 | 427,512,219.91 | 616,097,235.12 | 507,482,770.74 |
| 筹资活动产生的现金流量净额 | -620,926,293.36 | -411,603,686.33 | -394,202,704.16 | -393,737,649.19 |
| 汇率变动对现金及现金等价物的影响 | -19,169,139.06 | 11,117,107.32 | -13,551,197.53 | -6,458,287.49 |
| 现金及现金等价物净增加额 | -618,131,269.54 | -493,386,458.73 | 423,283,267.44 | 8,931,585.59 |
| 期末现金及现金等价物余额 | 2,227,676,547.52 | 2,352,420,648.98 | 2,845,807,817.06 | 2,431,456,135.21 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -618,131,269.54 | - | 423,283,267.44 | - |
最新报告期：2026-09-07| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中泰证券 | 祝嘉琦,谢木青 | 0.84 | 1.07 | 1.31 | 2026-09-07 |
| 国金证券 | 甘坛焕 | 0.87 | 1.12 | 1.30 | 2026-08-24 |